Navigation Links
BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/17/2009

ting loss of $10.9 million in 2007.

Non-GAAP net income was $7.2 million, or $0.19 per diluted share, in 2008 compared to a net loss of $9.0 million, or $0.32 per share, in 2007. On a GAAP basis, the Company reported a net loss of $3.4 million in 2008, compared to $11.6 million in 2007.

Balance Sheet

As of December 31, 2008, the Company had cash and cash equivalents of $15.7 million and notes receivable of $15.8, totaling $31.5 million. Notes receivables are notes accepted from customers for the settlement of trade receivable balances. All notes receivables are guaranteed by established banks in China and have maturities of six months or less.

Financial Guidance

As previously announced, for the fiscal year 2009, revenue is anticipated to increase at least 35% year over year to reach $150 to $160 million.

The Company announced today that it expects EBITDA for the full year 2009 to reach $16 million to $18 million.

The Company is also adjusting its 2009 net income guidance to reflect interest costs and debt discount amortization related to newly issued convertible debt due in July 2011. The Company expects GAAP net income to be between $2 million and $4 million and expects non-GAAP net income to be between $9 million and $11 million.

David Gao, Chief Executive Officer of BMP Sunstone, stated, "We expect 2009 to be another record year for our Company, with revenue growth of over 35% at the low end of our guidance range. We are actively transforming BMP Sunstone from a low margin distribution business into a high margin OTC and prescription specialty pharmaceutical company, and our guidance for 2009 reflects a more mature, diversified company with significant ability to drive shareholder value."

Gao continued, "Our 2009 financial guidance reflects sales and marketing expansion in China resulting from continued performance
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BMP Sunstone to Present at UBS Global Healthcare Services Conference
2. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
3. BMP Sunstone Receives High Tech Status
4. BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference
5. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
6. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. BMP Sunstone Announces Participation in November Investor Conferences
9. BMP Sunstone Announces Participation in September Investor Conference
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... RURO, Inc., a leading LIMS, ... Limfinity® version 5.1.4. , RURO’s deployment teams have ... ever in RURO’s 8 year history. Many deployments ... Limfinity® version 5.1.4 is the perfect example – ... fixes! , Limfinity® 5.1.4 release highlights – more ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
... Personalized Medicine Conference is bringing together the wide variety of stakeholders ... opportunities and challenges facing those involved in the development and realization ... ... 10, 2009 -- Arrowhead,s 2009 Personalized Medicine Conference is ...
... System Will Continue to Fuel Growth and Generate CashNEW YORK, ... Vice President James C. Borel said today he expects DuPont ... share by at least 1 to 2 points in 2009 ... DuPont Agriculture & Nutrition segment an average of at least ...
Cached Biology Technology:Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 2The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Academic Affairs John Wiecha, MD, MPH, in the Department ... Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge ... valued at more than $950,000 will fund a study ... diabetes. The health education will be conducted either ...
... years ago, vertebrates lacked the ability to chew their food. ... a flexible, fused basket of cartilage. This week, an ... the University of Colorado at Boulder published evidence that three ... development of jaws in higher vertebrates. The finding is ...
... adverts, the secret of fertility might not be eternal youth. ... Research at the Consejo Superior de Investigaciones Cientficas in Seville, ... have evolved to protect their seeds. His research is published ... Botany ( http://dx.doi.org/10.1093/aob/mcq160 ). Prof. Herrera said: "No ...
Cached Biology News:Wiecha receives grant to study face-to-face vs. virtual health education for African-American women 2Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team 2
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Tube-O-DIALYZER Floats, small....
Biology Products: